NervGen Pharma Corp. Common stock (NGEN)

• Market cap: $448M
• 1 day: -1.74%
• 5 days: -10.32%
• 1 month: -5.36%
• 3 months: -5.36%
• 6 months: -5.36%
• Year to date: -5.36%
• 1 year: -5.36%
• 5 years: -5.36%
• 10 years: -5.36%
• Sector: Healthcare
• Industry: Biotechnology

About: NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Employees: 14